华宝医药生物混合C(019029)资产负债表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 资产 |
| 银行存款 |
- |
- |
- |
- |
| 结算备付金 |
10,934,737.66 |
1,333,800.95 |
1,161,936.88 |
2,337,920.17 |
| 存出保证金 |
240,065.89 |
284,650.00 |
253,330.83 |
403,934.21 |
| 交易性金融资产 |
512,089,189.41 |
462,392,458.53 |
464,742,549.97 |
461,697,040.18 |
| 其中:股票投资 |
512,089,189.41 |
462,392,458.53 |
464,742,549.97 |
461,697,040.18 |
| 债券投资 |
- |
- |
- |
- |
| 资产支持证券投资 |
- |
- |
- |
- |
| 衍生金融资产 |
- |
- |
- |
- |
| 买入返售金融资产 |
- |
- |
- |
- |
| 应收证券清算款 |
5,174,456.29 |
5,397,994.56 |
927,768.45 |
22,378,166.36 |
| 应收利息 |
- |
- |
- |
- |
| 应收股利 |
- |
- |
- |
- |
| 应收申购款 |
5,230,476.78 |
941,779.11 |
821,726.58 |
231,266.36 |
| 其他资产 |
- |
- |
- |
- |
| 资产总计 |
589,014,651.39 |
540,360,609.51 |
551,744,244.50 |
549,888,190.96 |
| 负 债 |
| 短期借款 |
- |
- |
- |
- |
| 交易性金融负债 |
- |
- |
- |
- |
| 衍生金融负债 |
- |
- |
- |
- |
| 卖出回购金融资产款 |
- |
- |
- |
- |
| 应付证券清算款 |
9,817,610.10 |
- |
26,134,524.43 |
- |
| 应付赎回款 |
1,618,162.44 |
2,267,465.83 |
2,449,747.65 |
1,089,655.59 |
| 应付管理人报酬 |
503,485.23 |
582,285.75 |
560,496.59 |
624,551.88 |
| 应付托管费 |
83,914.22 |
97,047.62 |
93,416.12 |
104,091.98 |
| 应付销售服务费 |
67,396.68 |
14,819.24 |
6,893.05 |
27,742.44 |
| 应付交易费用 |
- |
- |
- |
- |
| 应交税费 |
181.41 |
- |
- |
1.34 |
| 应付利息 |
- |
- |
- |
- |
| 应付利润 |
- |
- |
- |
- |
| 其他负债 |
978,383.56 |
1,177,519.01 |
1,313,749.58 |
3,595,680.13 |
| 负债合计 |
13,069,133.64 |
4,139,137.45 |
30,558,827.42 |
5,441,723.36 |
| 所有者权益 |
| 实收基金 |
190,959,468.66 |
175,777,289.58 |
163,533,097.42 |
246,705,093.51 |
| 未分配利润 |
384,986,049.09 |
360,444,182.48 |
357,652,319.66 |
297,741,374.09 |
| 所有者权益合计 |
575,945,517.75 |
536,221,472.06 |
521,185,417.08 |
544,446,467.60 |
| 负债及所有者权益总计 |
589,014,651.39 |
540,360,609.51 |
551,744,244.50 |
549,888,190.96 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年